Sana Biotechnology 관리

관리 기준 확인 3/4

Sana Biotechnology CEO는 Steve Harr, Sep2018 에 임명되었습니다 의 임기는 6.17 년입니다. 총 연간 보상은 $ 2.67M, 24.7% 로 구성됩니다. 24.7% 급여 및 75.3% 보너스(회사 주식 및 옵션 포함). 는 $ 23.11M 가치에 해당하는 회사 주식의 3.97% 직접 소유합니다. 23.11M. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 5.3 년입니다.

주요 정보

Steve Harr

최고 경영자

US$2.7m

총 보상

CEO 급여 비율	24.7%
CEO 임기	6.2yrs
CEO 소유권	4.0%
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

CEO 보상 분석

Steve Harr 의 보수는 Sana Biotechnology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$306m
Jun 30 2024	n/a	n/a	-US$245m
Mar 31 2024	n/a	n/a	-US$309m
Dec 31 2023	US$3m	US$659k	-US$283m
Sep 30 2023	n/a	n/a	-US$276m
Jun 30 2023	n/a	n/a	-US$362m
Mar 31 2023	n/a	n/a	-US$320m
Dec 31 2022	US$4m	US$645k	-US$269m
Sep 30 2022	n/a	n/a	-US$300m
Jun 30 2022	n/a	n/a	-US$298m
Mar 31 2022	n/a	n/a	-US$207m
Dec 31 2021	US$1m	US$611k	-US$356m
Sep 30 2021	n/a	n/a	-US$358m
Jun 30 2021	n/a	n/a	-US$327m
Mar 31 2021	n/a	n/a	-US$433m
Dec 31 2020	US$7m	US$535k	-US$285m

보상 대 시장: Steve 의 총 보상 ($USD 2.67M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.16M ).

보상과 수익: Steve 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Steve Harr (54 yo)

6.2yrs

테뉴어

US$2,671,662

보상

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

리더십 팀

이름	위치	테뉴어	보상	소유권
Steven Harr	President	6.2yrs	US$2.67m	3.97% $ 23.1m
Susan Wyrick	Acting CFO	less than a year	데이터 없음	0.066% $ 385.0k
Snehal Patel	Senior VP & Chief Technical Officer	less than a year	데이터 없음	데이터 없음
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	less than a year	데이터 없음	데이터 없음
Bernard Cassidy	Executive VP	2.2yrs	US$4.26m	0.042% $ 242.2k
Sonja Schrepfer	Senior VP & Head of Hypoimmune Platform	5.8yrs	데이터 없음	데이터 없음
Farah Anwar	Head of Development Operations	4yrs	데이터 없음	데이터 없음
Gary Meininger	Chief Medical Officer	1.6yrs	데이터 없음	데이터 없음
Yuko Soneoka	Head of Intellectual Property	less than a year	데이터 없음	데이터 없음
John Gerecitano	Head of Oncology Research & Development	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: SANA 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Steven Harr	President	6.1yrs	US$2.67m	3.97% $ 23.1m
Robert Taylor Nelsen	Independent Director	6.1yrs	US$294.80k	0.0062% $ 36.1k
Mary Wilderotter	Independent Director	4.5yrs	US$314.80k	0.0032% $ 18.5k
Douglas Cole	Independent Director	4.6yrs	US$302.30k	0.091% $ 528.1k
Patrick Yang	Independent Director	6.1yrs	US$299.80k	0.067% $ 389.6k
Michelle Seitz	Independent Director	4yrs	US$314.80k	0% $ 0
Richard Mulligan	Vice Chairman	6yrs	데이터 없음	1.21% $ 7.0m
Hans Edgar Bishop	Independent Chairman of the Board	6.1yrs	US$354.80k	2.59% $ 15.1m
Joshua Bilenker	Independent Director	3.9yrs	US$299.80k	0.0090% $ 52.2k
Alise Reicin	Independent Director	3.9yrs	US$302.30k	0% $ 0

5.3yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: SANA 의 이사회는 경험(평균 재직 기간 5.3 년)으로 간주됩니다.

Sana Biotechnology 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Independent Director recently sold US$236k worth of stock

Insufficient new directors

Recent updates

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-Cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index

Sana Biotechnology reports Q1 results

Sana Biotechnology to Present Pre-Clinical Data At American Society of Gene & Cell Therapy Annual Meeting 2021

Sana Biotechnology, Inc. has completed an IPO in the amount of $587.5 million.

CEO 보상 분석

CEO

테뉴어

보상